A new model of heart failure with preserved ejection fraction induced by metabolic syndrome in Ossabaw miniature swine DOI Creative Commons
Xian‐Liang Tang,

Mouhamad Alloosh,

Qinghui Ou

et al.

Basic Research in Cardiology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction DOI
Dirk J. van Veldhuisen, Alain Cohen‐Solal, Michael Böhm

et al.

Journal of the American College of Cardiology, Journal Year: 2009, Volume and Issue: 53(23), P. 2150 - 2158

Published: June 1, 2009

Language: Английский

Citations

456
Acute Heart Failure Syndromes in Patients With Coronary Artery Disease DOI Creative Commons
James D. Flaherty, Jeroen J. Bax, Leonardo De Luca

et al.

Journal of the American College of Cardiology, Journal Year: 2009, Volume and Issue: 53(3), P. 254 - 263

Published: Jan. 1, 2009

Language: Английский

Citations

143
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction DOI Creative Commons
Rohan Samson, Abhishek Jaiswal, Pierre Vladimir Ennezat

et al.

Journal of the American Heart Association, Journal Year: 2016, Volume and Issue: 5(1)

Published: Jan. 13, 2016

Language: Английский

Citations

125
Responsive probes for in vivo magnetic resonance imaging of nitric oxide DOI
Chang Lu,

Shiyi Liao,

Baode Chen

et al.

Nature Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 25, 2024

Language: Английский

Citations

12
Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications DOI
Paul S. Pagel,

Justin N. Tawil,

Brent T. Boettcher

et al.

Journal of Cardiothoracic and Vascular Anesthesia, Journal Year: 2020, Volume and Issue: 35(6), P. 1839 - 1859

Published: July 9, 2020

Language: Английский

Citations

66
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design DOI Creative Commons
Lars H. Lund,

Stefan James,

Adam D. DeVore

et al.

European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 16, 2024

Aims Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex expensive. The Spironolactone Initiation Registry Randomized Interventional Trial Heart Failure Preserved Ejection Fraction (SPIRRIT‐HFpEF) is a unique pragmatic registry‐based trial. Methods SPIRRIT‐HFpEF multicentre, prospective, randomized, open‐label, blinded endpoint trial conducted on platforms the Swedish (SwedeHF) United States (US) Innovation Network. Patients HFpEF/HFmrEF 1:1 to spironolactone (or eplerenone) addition usual care, versus care alone. primary outcome total number cardiovascular deaths hospitalizations for failure. Outcomes collected from administrative complete coverage registries US call centre subsequently adjudicated. Simple eligibility criteria were based data available SwedeHF: as outpatient or at discharge hospital, left ventricular ≥40%, N‐terminal pro‐B‐type natriuretic peptide >300 ng/L (in sinus rhythm) >750 atrial fibrillation), pre‐specified adjustment elevated body mass index, chronic loop diuretic use. Power sample size assessments an event‐driven design allowing enrolment over approximately 6 years, application hazard ratios TOPCAT trial, Americas subset. final expected be 2400 patients. Conclusion will informative effectiveness generic MRAs HFpEF HFmrEF, feasibility conducting other conditions.

Language: Английский

Citations

5
Atrial Fibrillation and Race – A Contemporary Review DOI

Michael Amponsah,

Emelia J. Benjamin, Jared W. Magnani

et al.

Current Cardiovascular Risk Reports, Journal Year: 2013, Volume and Issue: 7(5), P. 336 - 345

Published: Aug. 6, 2013

Language: Английский

Citations

53
The Aging Heart in Focus: The Advanced Understanding of Heart Failure with Preserved Ejection Fraction DOI

Zhe-Wei Zhang,

Yibin Wang, Xiangqi Chen

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 101, P. 102542 - 102542

Published: Oct. 12, 2024

Language: Английский

Citations

4
Propensity score matched cohort study on magnesium supplementation and mortality in critically ill patients with HFpEF DOI Creative Commons

Lijun Song,

Jianjun Ying,

Man Li

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 14, 2025

Heart failure with preserved ejection fraction (HFpEF) emerges as a singular subclass of heart failure, bereft specific therapeutic options. Magnesium, an indispensable trace element, is essential to the preservation cardiac integrity. However, association between magnesium supplementation and mortality in HFpEF patients remains unclear. This study extracted patient data from MIMIC-IV database 2008 2019. Propensity score matching was conducted ensure that receiving (including sulfate oxide) were balanced those not it terms baseline characteristics. The primary analysis focused on 28-day all-cause rate, secondary endpoints encompassing ICU one-year rates, along duration hospitalization. After matching, study's final cohort at 1970 patients, 985 per group. results showed intake significantly contributed decrease rate (hazard ratio [HR], 0.682; 95% confidence interval [CI], 0.539–0.863), particularly subgroups such older (HR, 0.65; CI 0.52–0.81), females 0.55; 0.41–0.73), hypertension 0.62; 0.48–0.79) or without diabetes 0.54; 0.41–0.71). Although treatment improved both concurrently resulted extended hospital stays. Mediation indicated blood urea nitrogen partially mediated mortality, accounting for approximately 22.73% observed effect. Magnesium has illustrated significant potential mitigating patient, among elderly, female, individuals hypertension. Therefore, stands potentially valuable supplementary modality HFpEF. Further comprehensive research warranted explore its effects more deeply.

Language: Английский

Citations

0
Health‐related quality of life across heart failure categories: associations with clinical characteristics and outcomes DOI Creative Commons
Camilla Settergren,

Lina Benson,

Ulf Dahlström

et al.

ESC Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

Abstract Aims The study aims to examine characteristics and outcomes associated with health‐related quality of life (HRQoL) in patients heart failure (HF) preserved, mildly reduced ejection fraction (EF) (HFpEF, HFmrEF HFrEF). Methods results Data on HRQoL were collected the Swedish Heart Failure Registry (SwedeHF; 2000–2021) using EuroQoL 5‐dimensional visual analogue scale (EQ 5D‐vas). Baseline EQ 5D‐vas scores categorized as ‘best’ (76–100), ‘good’ (51–75), ‘bad’ (26–50) ‘worst’ (0–25). Independent associations between patients' 5D‐vas, well assessed. Of 40 809 (median age 74 years; 32% female), 29% ‘best’, 41% ‘good’, 25% 5% categories, similarly distributed across all EF categories. Higher New York Association (NYHA) class was strongly lower regardless followed by chronic obstructive pulmonary disease, smoking, body mass index, higher rate, anaemia, previous stroke, ischaemic use diuretics living alone, whereas income, male sex, outpatient status systolic blood pressure inversely Patients category compared had highest risk all‐cause death [adjusted hazard ratios 1.97, 95% confidence interval (CI) 1.64–2.37 HFrEF, 1.77, CI 1.30–2.40 1.43 1.02–2.00 HFpEF]. Conclusions Most two NYHA strongest association worst at mortality.

Language: Английский

Citations

0